R

Radiopharm Theranostics Ltd
ASX:RAD

Watchlist Manager
Radiopharm Theranostics Ltd
ASX:RAD
Watchlist
Price: 0.029 AUD 61.11% Market Closed
Market Cap: 80.6m AUD
Section:
 

Relative Value

The Relative Value of one RAD stock under the Base Case scenario is hidden AUD. Compared to the current market price of 0.029 AUD, Radiopharm Theranostics Ltd is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

RAD Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Valuation Multiples

22.2
P/S
P/S
Price to Sales
22.2
vs History
47
vs Industry
24
Median 3Y
20.7
Median 5Y
0
Industry
7.9
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-2.3
Median 5Y
-6
Industry
23.7
Forward
-1.3
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
Median 3Y
-4.6
Median 5Y
-9
Industry
22
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-5
Median 5Y
-8.4
Industry
23.8
More Details
1.8
P/B
P/B
Price to Book Value
1.8
vs History
94
vs Industry
57
Median 3Y
3.8
Median 5Y
5.1
Industry
3.3
More Details
14.2
EV/S
EV/S
Enterprise Value to Sales
14.2
vs History
47
vs Industry
30
Median 3Y
12.7
Median 5Y
0
Industry
8.3
More Details
1 311
EV/GP
EV/GP
Enterprise Value to Gross Profit
1 311
vs History
11
vs Industry
Median 3Y
0
Median 5Y
0
Industry
10.1
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
Median 3Y
-2.4
Median 5Y
-5.7
Industry
6.4
Forward
-1.2
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
Median 3Y
-2.4
Median 5Y
-5.7
Industry
7
Forward
-0.6
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
Median 3Y
-3.8
Median 5Y
-8.9
Industry
8.3
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
Median 3Y
-3.8
Median 5Y
-8.4
Industry
6.5
More Details
1
EV/IC
EV/IC
Enterprise Value to IC
1
vs History
94
vs Industry
65
Median 3Y
2
Median 5Y
3.3
Industry
5.7
More Details

Multiples Across Competitors

RAD Competitors Multiples
Radiopharm Theranostics Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
AU
Radiopharm Theranostics Ltd
ASX:RAD
80.6m AUD 22.2 -2.1 -1.5 -1.5
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 738 486.8 -160 354 -194 720.9 -192 498.9
US
Abbvie Inc
NYSE:ABBV
396.8B USD 6.7 168.8 16.4 23.2
US
Amgen Inc
NASDAQ:AMGN
174B USD 4.8 25 18 18
US
Gilead Sciences Inc
NASDAQ:GILD
150.7B USD 5.2 18.5 12.5 12.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.3B USD 9.9 31.4 23 24
US
Epizyme Inc
F:EPE
94.1B EUR 2 088.1 -532.8 -580.2 -564.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79B USD 5.5 17.2 16.4 18.6
AU
CSL Ltd
ASX:CSL
85.8B AUD 3.7 19 12.8 16
NL
argenx SE
XBRU:ARGX
44.1B EUR 14.4 33.8 58.3 59.9
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
51.6B USD 16.1 1 191.4 155.5 188.6
P/E Multiple
Earnings Growth PEG
AU
R
Radiopharm Theranostics Ltd
ASX:RAD
Average P/E: 188.2
Negative Multiple: -2.1 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 354 N/A N/A
US
Abbvie Inc
NYSE:ABBV
168.8
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
25
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
18.5
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
31.4
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -532.8 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.2
9%
1.9
AU
CSL Ltd
ASX:CSL
19
11%
1.7
NL
argenx SE
XBRU:ARGX
33.8
40%
0.8
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 191.4
N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
AU
R
Radiopharm Theranostics Ltd
ASX:RAD
Average EV/EBITDA: 39.1
Negative Multiple: -1.5 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 720.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.4
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18
11%
1.6
US
Gilead Sciences Inc
NASDAQ:GILD
12.5
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -580.2 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.4
11%
1.5
AU
CSL Ltd
ASX:CSL
12.8
8%
1.6
NL
argenx SE
XBRU:ARGX
58.3
839%
0.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
155.5
N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
AU
R
Radiopharm Theranostics Ltd
ASX:RAD
Average EV/EBIT: 45.1
Negative Multiple: -1.5 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 498.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.2
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.5
12%
1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -564.7 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.6
13%
1.4
AU
CSL Ltd
ASX:CSL
16
11%
1.5
NL
argenx SE
XBRU:ARGX
59.9
N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
188.6
N/A N/A

See Also

Summary
RAD intrinsic value, competitors valuation, and company profile.
DCF Valuation
RAD stock valuation using Discount Cash Flow valuation method.
Relative Valuation
RAD stock valuation using valuation multiples.
Wall Street Estimates
RAD price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
RAD stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 303,400+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.